💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Krebs Biochemicals & Industries Ltd is an India-based company, which is engaged in the business of manufacture of active pharmaceutical ingredients. The Company manufactures bulk active pharmaceutical ingredients, pharmaceutical intermediates, fine chemicals, nutraceuticals…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak business — but carrying elevated distress risk.
KREBS BIOCHEMICALS & INDUSTRIES is scored on the pharma / healthcare framework. It keeps a thin -65.7% of every rupee of sales as net profit. Free cash flow is worth about -4.6% of its market value.
Return on equity is a weak 7.8%.
It trades at -9× earnings. The books come through clean — a forensic grade of B, and Altman puts distress risk in the distress zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | -9.03 | — | — |
| P/B | — | 4.1 | — |
| EV/EBITDA | — | 19.33 | — |
| ROE | 7.82 | — | — |
| ROCE | -5.72 | 14.41 | worse |
| ROA | -8.41 | 1.64 | worse |
| Quick Ratio | 0.03 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue declined 41% in the latest year — a break from prior trajectory. Negative CAGR — the top line has shrunk over this window. Growth is decelerating — latest year grew slower than the year before.
4 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a +37% swing — check if it's a one-off or structural.
Operating margin has compressed from -47% to -66% — costs or competition are eating into profitability.
3 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 18% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (34% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate fading — recent quarters 19% below earlier ones.
4 of 4 quarters loss-making — quarterly profitability is uneven. Profit fell 118% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (-43% → -93%) — more revenue isn't translating to proportionally more profit.
P/E band unavailable — needs 5y of consistent EPS + price history.
Promoters hold 72.7% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.